Blood cancers

CAR-T cell therapy still on the drawing board over composition & timing

Maximising the curative potential of chimeric antigen receptor (CAR) T cells will require a multi-pronged approach – improving CAR and cell product design, multivalent targeting and optimal timing of use. Speaking to the limbic at Blood 2018, Professor Stan Riddell said the adoption of uniform ratios of CD4+ and CD8+ T cells in the cell ...

Already a member?

Login to keep reading.

© 2021 the limbic